SCHEMBL2842840

SCHEMBL2842840

CC(Nc1nc2ccc(Oc3ccnc(-c4ccncc4)n3)cc2s1)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 12/20 0.48
PDGFRB P09619 2/20 0.41
KIT P10721 2/20 0.41
PDGFRA P16234 2/20 0.41
FLT3 P36888 2/20 0.41
MAPT P10636 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
PKM P14618 1/20 0.40
PI4KA P42356 2/20 0.40
PI4KB Q9UBF8 2/20 0.40
PIP5K1C O60331 1/20 0.40
PIK3CG P48736 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
USP30 Q70CQ3 2/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2842831 1.00 CSF1R (0.48) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2845793 0.90 CSF1R (0.48) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2845787 0.90 CSF1R (0.48) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2843107 0.88 CSF1R (0.39) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2842980 0.88 CSF1R (0.44) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2843106 0.88 CSF1R (0.39) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2842986 0.88 CSF1R (0.44) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2846300 0.86 CSF1R (0.46) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2846296 0.86 CSF1R (0.46) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2677385 0.86 CSF1R (0.49) CSF1RPDGFRBKITPDGFRAFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 EP claimed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US claimed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US claimed
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 EP disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 CSF1R 1/4885PDGFRB 119/4885KIT 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.